Gemcitabine-associated thrombotic microangiopathy (Q33361258)

26 July 2017

title

Gemcitabine-associated thrombotic microangiopathy (English)

1 reference

26 July 2017

Joel M Henderson

0 references

Benjamin D Humphreys

1 reference

26 July 2017

Jeff P Sharman

1 reference

26 July 2017

Jeffrey W Clark

1 reference

26 July 2017

Peter W Marks

1 reference

26 July 2017

Helmut G Rennke

1 reference

26 July 2017

Andrew X Zhu

1 reference

26 July 2017

Colm C Magee

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

26 July 2017

1 reference

26 July 2017

volume

100

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

2664-2670

1 reference

A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

Thrombotic Microangiopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

Thrombotic microangiopathy (thrombotic thrombocytopenic purpura) associated with acute haemorrhagic leucoencephalitis and sensitivity to oxophenarsine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

Drug-induced thrombotic microangiopathy: incidence, prevention and management

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

Gemcitabine-associated hemolytic-uremic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

Prognostic importance of vascular lesions in acute renal failure with microangiopathic hemolytic anemia (hemolytic-uremic syndrome): Clinicopathologic study in 20 adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

Renal vascular lesions after chemotherapy with vinblastine, bleomycin, and cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

Radiation nephropathy after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

FK506-associated thrombotic microangiopathy: report of two cases and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

Cyclosporine and tacrolimus-associated thrombotic microangiopathy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20290

7 January 2021

Identifiers

DOI

10.1002/CNCR.20290

1 reference

26 July 2017

1 reference